Get the Stockscreener App
2.99
5.28%
0.15
Quantum Biopharma Ltd stock is traded at $2.99, with a volume of 37,263.
It is up +5.28% in the last 24 hours and down -23.53% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$2.84
Open:
$2.86
24h Volume:
37,263
Relative Volume:
0.11
Market Cap:
$19.13M
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.3619
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
-7.72%
1M Performance:
-23.53%
6M Performance:
-51.62%
1Y Performance:
-74.91%
1-Day Range:
$2.78
$2.99
1-Week Range:
$2.695
$3.27
52-Week Range:
$2.07
$15.96
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
2.99 | 19.13M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – SWB:0K91 - TradingView
QNTM|Quantum BioPharma Ltd|Price:2.990|Chg%:+0.150 - TradingKey
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
QNTM|Quantum BioPharma Ltd|Price:2.790|Chg%:-0.050 - TradingKey
QNTM: Quantum BioPharma Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Quantum BioPharma Ltd (QNTM) Fundamental & Financial Data - Stocktwits
Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - TradingView
Quantum BioPharma Plans to Settle Debt - marketscreener.com
Press Release: Quantum BioPharma Announces Intention to Settle Debt - Moomoo
Quantum BioPharma Announces Intention to Settle Debt - Sahm
Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance - Quiver Quantitative
5 Stocks To BUY HEAVY Before June 2026 Pentagone Ovnis (uU0VmOjAyP) - Mshale
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy - USA Today
Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy - NewMediaWire
Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development Of Neuroprotective Therapy - Menafn
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials - citybuzz -
Why Quantum BioPharma (QNTM) Is 'One to Watch' - NewMediaWire
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’ - Benzinga
Why Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Is 'One To Watch' - Menafn
Quantum BioPharma Advances Diversified Pipeline Targeting Neurodegenerative and Metabolic Disorders - citybuzz -
Quantum Biopharma Ltd. Q4 2025 Earnings: Widening Loss Amid Pre-Revenue Drug DevelopmentEarnings Volatility Report - DonanımHaber
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Biotech Firm Reports Wider-Than-Expected Loss as Stock SlipsLow Estimate Range - dars.gov.et
AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM) - Stock Titan
Quantum BioPharma Provides Corporate Update - BNN Bloomberg
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - The Globe and Mail
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Yahoo Finance
QNTM Q4 2025 Earnings: Biotech Reports Loss with No Revenue, Stock DeclinesEarnings Surprise Score - dars.gov.et
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - TipRanks
Quantinuum (QNTM) Receives Strong Ratings, Shares Rise 5% in Pre-Market - GuruFocus
Quantum Biopharma Q4 2025 Earnings: Reports net loss of $0.71 per share as clinical‑stage biotech continues operationsFinancial Summary - dars.gov.et
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
Quantum BioPharma's Lucid-MS Targets Underlying Cause of Multiple Sclerosis in Growing $38.6B Market - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (NASDAQ:QNTM) - TradingView
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum BioPharma’s Lucid-MS Aims to Fill Void in Multiple Sclerosis Treatment - citybuzz -
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy - GlobeNewswire
Quantum BioPharma advances Lucid-MS, a novel pa... - Pluang
Quantum BioPharma Company Profile & Introduction - Moomoo
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis - citybuzz -
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAM:0K91 - TradingView
The Quest to Repair What Multiple Sclerosis Takes Away - Caledon Enterprise
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - Sahm
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):